Terms: = Pancreatic cancer AND WT1, WAGR, 7490, ENSG00000184937, WT33, GUD, WIT-2 AND Treatment
19 results:
1. Nomogram for predicting the preoperative lymph node metastasis in resectable pancreatic cancer.
Cheng H; Xu JH; Kang XH; Liu XM; Wang HF; Wang ZX; Pan HQ; Zhang QQ; Xu XL
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12469-12477. PubMed ID: 37442865
[TBL] [Abstract] [Full Text] [Related]
2. CD169 Defines Activated CD14
Affandi AJ; Olesek K; Grabowska J; Nijen Twilhaar MK; Rodríguez E; Saris A; Zwart ES; Nossent EJ; Kalay H; de Kok M; Kazemier G; Stöckl J; van den Eertwegh AJM; de Gruijl TD; Garcia-Vallejo JJ; Storm G; van Kooyk Y; den Haan JMM
Front Immunol; 2021; 12():697840. PubMed ID: 34394090
[TBL] [Abstract] [Full Text] [Related]
3. Desmoplastic Small Round Cell Tumor of pancreatic Origin in a Young Child: A Case Report and Review of Literature.
Saleh D; Al-Maghrabi S; Al-Maghrabi H; Al-Maghrabi J
Am J Case Rep; 2020 Jul; 21():e922762. PubMed ID: 32655125
[TBL] [Abstract] [Full Text] [Related]
4. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with wt1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.
Katsuda M; Miyazawa M; Ojima T; Katanuma A; Hakamada K; Sudo K; Asahara S; Endo I; Ueno M; Hara K; Yamada S; Fujii T; Satoi S; Ioka T; Ohira M; Akahori T; Kitano M; Nagano H; Furukawa M; Adachi T; Yamaue H
Trials; 2019 Apr; 20(1):242. PubMed ID: 31029154
[TBL] [Abstract] [Full Text] [Related]
5. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with wt1-targeted dendritic cell vaccines.
Hanada S; Tsuruta T; Haraguchi K; Okamoto M; Sugiyama H; Koido S
Hum Vaccin Immunother; 2019; 15(2):397-406. PubMed ID: 30230959
[TBL] [Abstract] [Full Text] [Related]
6. [wt1 Class I Peptide/wt1 Class II Peptide Pulsed Dendritic Cell Therapy Efficacy in 60 Patients with a Wide Range of Advanced cancers].
Kato Y
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1252-1255. PubMed ID: 27760951
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy.
Tsukinaga S; Kajihara M; Takakura K; Ito Z; Kanai T; Saito K; Takami S; Kobayashi H; Matsumoto Y; Odahara S; Uchiyama K; Arakawa H; Okamoto M; Sugiyama H; Sumiyama K; Ohkusa T; Koido S
World J Gastroenterol; 2015 Oct; 21(39):11168-78. PubMed ID: 26494971
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted wt1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer.
Takakura K; Koido S; Kan S; Yoshida K; Mori M; Hirano Y; Ito Z; Kobayashi H; Takami S; Matsumoto Y; Kajihara M; Misawa T; Okamoto M; Sugiyama H; Homma S; Ohkusa T; Tajiri H
Anticancer Res; 2015 Jan; 35(1):555-62. PubMed ID: 25550602
[TBL] [Abstract] [Full Text] [Related]
9. [Efficacy of wt1 peptide-/MUC-1 peptide-pulsed dendritic cell therapy in 313 patients with a wide range of cancers].
Kato Y
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1280-2. PubMed ID: 25335717
[TBL] [Abstract] [Full Text] [Related]
10. treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (wt1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
[TBL] [Abstract] [Full Text] [Related]
11. P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma.
Terashima T; Mizukoshi E; Arai K; Yamashita T; Yoshida M; Ota H; Onishi I; Kayahara M; Ohtsubo K; Kagaya T; Honda M; Kaneko S
Cancer Immunol Immunother; 2014 May; 63(5):479-89. PubMed ID: 24633336
[TBL] [Abstract] [Full Text] [Related]
12. Wilms tumor gene (wt1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.
Nishida S; Koido S; Takeda Y; Homma S; Komita H; Takahara A; Morita S; Ito T; Morimoto S; Hara K; Tsuboi A; Oka Y; Yanagisawa S; Toyama Y; Ikegami M; Kitagawa T; Eguchi H; Wada H; Nagano H; Nakata J; Nakae Y; Hosen N; Oji Y; Tanaka T; Kawase I; Kumanogoh A; Sakamoto J; Doki Y; Mori M; Ohkusa T; Tajiri H; Sugiyama H
J Immunother; 2014; 37(2):105-14. PubMed ID: 24509173
[TBL] [Abstract] [Full Text] [Related]
13. Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies.
Festa V; Andriulli A; Valvano MR; Uomo G; Perri F; Andriulli N; Corrao S; Koch M
JOP; 2013 Nov; 14(6):618-25. PubMed ID: 24216547
[TBL] [Abstract] [Full Text] [Related]
14. [wt1-targeting cancer vaccine].
Sugiyama H
Nihon Rinsho; 2012 Dec; 70(12):2105-13. PubMed ID: 23259381
[TBL] [Abstract] [Full Text] [Related]
15. Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial).
Okusaka T; Ueno M; Sato T; Heike Y
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):314-8. PubMed ID: 22273718
[TBL] [Abstract] [Full Text] [Related]
16. Gemcitabine enhances Wilms' tumor gene wt1 expression and sensitizes human pancreatic cancer cells with wt1-specific T-cell-mediated antitumor immune response.
Takahara A; Koido S; Ito M; Nagasaki E; Sagawa Y; Iwamoto T; Komita H; Ochi T; Fujiwara H; Yasukawa M; Mineno J; Shiku H; Nishida S; Sugiyama H; Tajiri H; Homma S
Cancer Immunol Immunother; 2011 Sep; 60(9):1289-97. PubMed ID: 21607557
[TBL] [Abstract] [Full Text] [Related]
17. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer.
Soeda A; Morita-Hoshi Y; Makiyama H; Morizane C; Ueno H; Ikeda M; Okusaka T; Yamagata S; Takahashi N; Hyodo I; Takaue Y; Heike Y
Jpn J Clin Oncol; 2009 Dec; 39(12):797-806. PubMed ID: 19797418
[TBL] [Abstract] [Full Text] [Related]
18. Wilms' tumour gene 1 (wt1) as a target in curcumin treatment of pancreatic cancer cells.
Glienke W; Maute L; Wicht J; Bergmann L
Eur J Cancer; 2009 Mar; 45(5):874-80. PubMed ID: 19196508
[TBL] [Abstract] [Full Text] [Related]
19. Overexpression of the Wilms' tumor gene wt1 in pancreatic ductal adenocarcinoma.
Oji Y; Nakamori S; Fujikawa M; Nakatsuka S; Yokota A; Tatsumi N; Abeno S; Ikeba A; Takashima S; Tsujie M; Yamamoto H; Sakon M; Nezu R; Kawano K; Nishida S; Ikegame K; Kawakami M; Tsuboi A; Oka Y; Yoshikawa K; Aozasa K; Monden M; Sugiyama H
Cancer Sci; 2004 Jul; 95(7):583-7. PubMed ID: 15245594
[TBL] [Abstract] [Full Text] [Related]
